Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Revenue (2016 - 2025)

Perspective Therapeutics' Revenue history spans 15 years, with the latest figure at $307000.0 for Q4 2024.

  • For Q4 2024, Revenue rose 106.26% year-over-year to $307000.0; the TTM value through Sep 2025 reached $307000.0, up 108.07%, while the annual FY2024 figure was $1.4 million, 1.95% down from the prior year.
  • Revenue for Q4 2024 was $307000.0 at Perspective Therapeutics, up from $300000.0 in the prior quarter.
  • Across five years, Revenue topped out at $3.0 million in Q3 2023 and bottomed at -$4.9 million in Q4 2023.
  • The 5-year median for Revenue is $2.4 million (2020), against an average of $1.6 million.
  • The largest YoY upside for Revenue was 106.26% in 2024 against a maximum downside of 90.02% in 2024.
  • A 5-year view of Revenue shows it stood at $2.4 million in 2020, then rose by 19.37% to $2.8 million in 2021, then plummeted by 39.03% to $1.7 million in 2022, then tumbled by 385.5% to -$4.9 million in 2023, then surged by 106.26% to $307000.0 in 2024.
  • Per Business Quant, the three most recent readings for CATX's Revenue are $307000.0 (Q4 2024), $300000.0 (Q3 2024), and $503000.0 (Q2 2024).